natgillin/translations-raw huggingface dataset:
The maximum plasma concentration of the fast-acting insulin is reached within 1.5-2.5 hours after subcutaneous administration.
Največja koncentracija hitrodelujočega insulina v plazmi je dosežena v 1, 5 do 2, 5 urah po subkutani uporabi.
Distribution No profound binding to plasma proteins, except circulating insulin antibodies (if present) has been observed.
Porazdelitev Ugotovili niso nobene izrazite vezave na beljakovine v plazmi, razen na krožeča protitelesa proti insulinu (če so prisotna).
Metabolism Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
Presnova Opisano je, da se humani insulin razgradi z insulinsko proteazo ali encimi za razgradnjo insulina in morda s proteinsko disulfid- izomerazo.
A number of cleavage (hydrolysis) sites on the human insulin molecule have been proposed; none of the metabolites formed following the cleavage are active.
Predlagana so številna mesta razcepa (hidrolize) na molekuli humanega insulina; nobeden od presnovkov, nastalih po razcepu, ni aktiven.
Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Izločanje Končni razpolovni čas je določen s hitrostjo absorpcije iz podkožnega tkiva.
The terminal half-life (t½) is therefore a measure of the absorption rather than of the elimination per se of
Končni razpolovni čas (t1/ 2) je torej merilo absorpcije, ne izločanja insulina iz plazme per se (insulin v krvnem obtoku ima t1/ 2 nekaj minut).
Trials have indicated a t½ of about 5-10 hours.
Preskušanja so pokazala t1/ 2 približno 5- 10 ur.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
Neklinični podatki na podlagi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za ljudi.
Zinc chloride Glycerol Metacresol Phenol Disodium phosphate dihydrate Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Protamine sulphate Water for injections
cinkov klorid glicerol metakrezol fenol natrijev hidrogenfosfat dihidrat natrijev hidroksid (za uravnavo pH) klorovodikova kislina (za uravnavo pH) protaminijev sulfat voda za injekcije
Insulin products should only be added to compounds with which it is known to be compatible.
Na splošno je insulin dovoljeno dodajati le snovem, s katerimi je znano kompatibilen.
30 months when stored between 2°C - 8°C.
30 mesecev pri temparaturi od 2 do 8 °C.
6 weeks when used or stored at room temperature (below 25°C).
6 tednov, če bolnik uporablja zdravilo ali ga hrani pri sobni temperaturi (do 25 °C).
Before use: store in a refrigerator (2°C - 8°C).
Pred uporabo: shranjujte v hladilniku (med 2 °C in 8 °C).
During use: do not refrigerate.
Med uporabo: ne shranjujte v hladilniku!
Do not store above 25°C.
Shranjujte pri temperaturi do 25 °C!
Keep the vial in the outer carton in order to protect from light.
Vialo shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo!
Protect from excessive heat and sunlight.
Zavarujte pred čezmerno vročino in sončno svetlobo!
10 ml glass vial (type 1) closed with a bromobutyl/ polyisoprene rubber stopper and a protective tamper-proof cap.
10 ml steklena viala (steklo tipa 1), zaprta z zamaškom iz brombutil/ poliizoprenske gume in zaščitno varnostno zaporko.
1 and 5 vials x 10 ml and a multipack with 5 x (1 x 10 ml) vials.
1 in 5 vial x 10 ml in skupno pakiranje 5 x (1 x 10 ml) vial.
7 After removing Actraphane vial from the refrigerator it is recommended to allow the vial to reach room temperature (not above 25°C) before resuspending the insulin as instructed for first time use.
Potem, ko vialo insulina Actraphane vzamete iz hladilnika, jo je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilu za prvo uporabo.
Insulin suspensions should not be used if they do not appear uniformly white and cloudy after resuspension.
Suspenzij insulina se ne sme uporabiti, če po resuspendiranju niso enakomerno bele in motne.
Novo Nordisk A/ S Novo Allé DK-2880 Bagsværd Denmark
Novo Nordisk A/ S Novo Allé DK- 2880 Bagsværd Danska
07 October 2002
7. oktober 2002
Actraphane 30 100 IU/ ml suspension for injection in a vial.
Actraphane 30 100 i. e. / ml suspenzija za injiciranje v viali
1 vial contains 10 ml equivalent to 1000 IU.
1 ml vsebuje 100 i. e. humanega insulina 1 viala vsebuje 10 ml, kar ustreza 1000 i. e.
Renal or hepatic impairment may reduce insulin requirement.
Okvara ledvic ali jeter lahko zmanjšata potrebo po insulinu.
9 Adjustment of dosage may also be necessary if patients change physical activity or their usual diet.
9 Prilagoditev odmerjanja utegne biti potrebna tudi v primeru, da bolniki spremenijo svojo telesno dejavnost ali običajno prehrano.
10 A few patients who have experienced hypoglycaemic reactions after transfer from animal source insulin have reported that early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin.
10 Maloštevilni bolniki, ki so po prehodu z insulina živalskega izvora doživeli hipoglikemije, so navedli, da so bili zgodnji opozorilni simptomi hipoglikemije manj izraziti ali so se razlikovali od tistih, ki so jih doživeli s prejšnjim insulinom.
The physician must therefore take possible interactions into account and should always ask hispatients about any medicinal products they take.
Zdravnik mora zato upoštevati možna medsebojna delovanja in mora bolnike vedno povprašati po vseh zdravilih, ki jih uporabljajo.
Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta- blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids and sulphonamides.
Potrebo po insulinu lahko zmanjšajo naslednje snovi: peroralni antidiabetiki, zaviralci monoaminoksidaze (MAOI), neselektivni zaviralci adrenergičnih receptorjev beta, zaviralci encima angiotenzinske konvertaze (ACE), salicilati, alkohol, anabolni steriodi in sulfonamidi.
4.8 Undesirable effects
11 4. 8 Neželeni učinki
Therefore, no specific frequency can be presented.
Natančne pogostnosti zato ni mogoče navesti.
The frequencies are defined as: uncommon (≥ 1/ 1,000 to < 1/ 100).
Pogostnosti so opredeljene kot: občasni (≥ 1/ 1. 000, < 1/ 100).
Skin and subcutaneous tissue disorders Uncommon - Lipodystrophy Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.
Bolezni kože in podkožja Občasni – lipodistrofija Če bolnik mest injiciranj na posameznem predelu ne menja krožno, se lahko pojavi lipodistrofija.
12 4.9 Overdose
12 intravensko zdravstveni delavec.
Insulins and analogues for injection, intermediate-acting combined with fast-acting, insulin (human).
Farmakoterapevtska skupina: insulini in analogi za injiciranje, s srednje dolgim delovanjem, s takojšnjim učinkom, humani nisulin.
13 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Izločanje Končni razpolovni čas je določen s hitrostjo absorpcije iz podkožnega tkiva.
The terminal half-life (t½) is therefore a measure of the absorption rather than of the elimination per se of insulin from plasma (insulin in the blood stream has a t½ of a few minutes).
Končni razpolovni čas (t1/ 2) je torej merilo absorpcije, ne izločanja insulina iz plazme per se (insulin v krvnem obtoku ima t1/ 2 nekaj minut).
30 months when stored between 2ºC - 8ºC.
30 mesecev pri temparaturi od 2 do 8 °C.
6 weeks when used or stored at room temperature (below 25ºC).
6 tednov, če bolnik uporablja zdravilo ali ga hrani pri sobni temperaturi (do 25 °C).
Do not store them in or too near the freezer section or cooling element.
Neshranjujte v zamrzovalniku in ne preblizu zamrzovalnika ali hladilnega elementa.
14 After removing Actraphane vial from the refrigerator it is recommended to allow the vial to reach room temperature (not above 25°C) before resuspending the insulin as instructed for first time use.
Potem ko vialo insulina Actraphane vzamete iz hladilnika, jo je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilu za prvo uporabo.
Actraphane 10 Penfill 100 IU/ ml suspension for injection in a cartridge.
Actraphane 10 Penfill 100 i. e. / ml suspenzija za injiciranje v injekcijskem vložku
1 cartridge contains 3 ml equivalent to 300 IU.
1 ml vsebuje 100 i. e. humanega insulina 1 vložek vsebuje 3 ml, kar ustreza 300 i. e.
Actraphane 10 consists of 10% dissolved insulin and 90% isophane insulin.
Actraphane 10 vsebuje 10% raztopljenega insulina in 90% insulina izofan.
Suspension for injection in a cartridge.
Suspenzija za injiciranje v injekcijskem vložku.
16 Adjustment of dosage may also be necessary if patients change physical activity or their usual diet.
16 Prilagoditev odmerjanja utegne biti potrebna tudi v primeru, da bolniki spremenijo svojo telesno dejavnost ali običajno prehrano.
Insulin suspensions are never to be administered intravenously.
Suspenzij insulina nikoli ne smemo injicirati intravensko.
The cartridges are designed to be used with Novo Nordisk delivery systems (durable devices for repeated use) and NovoFine needles.
Vložki so namenjeni za uporabo z aplikacijskimi sistemi Novo Nordisk (za večkratno uporabo) in iglami NovoFine.
Detailed instruction accompanying the delivery system must be followed.
Upoštevati je treba podrobno navodilo, priloženo aplikacijskemu sistemu.
Reactions usually resolve in a few days to a few weeks.
Reakcije ponavadi minejo v nekaj
17 A few patients who have experienced hypoglycaemic reactions after transfer from animal source insulin have reported that early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin.
Maloštevilni bolniki, ki so po prehodu z insulina živalskega izvora doživeli hipoglikemije, so navedli, da so bili zgodnji opozorilni simptomi hipoglikemije manj izraziti ali so se razlikovali od tistih, ki so jih doživeli s prejšnjim insulinom.
Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta- blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids and sulphonamides.
Potrebo po insulinu lahko zmanjšajo naslednje snovi: peroralni antidiabetiki, zaviralci monoaminoksidaze( MAOI), neselektivni zaviralci adrenergičnih receptorjev beta, zaviralci encima angiotenzinske konvertaze (ACE), salicilati, alkohol, anabolni steroidi in sulfonamidi.
This is particularly important in those who have reduced or absent awareness of the warning signs of
To je posebno pomembno pri bolnikih z zmanjšanim ali
18 hypoglycaemia or have frequent episodes of hypoglycaemia.
18 odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
The frequencies are defined as: uncommon (≥ 1/ 1,000 to < 1/ 100).
Pogostnosti so opredeljene kot: občasni (≥ 1/ 1. 000 do < 1/ 100).
Immune system disorders Uncommon - Urticaria, rash Very rare – Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation, reduction in blood pressure and fainting/ loss of consciousness.
Bolezni imunskega sistema Občasni – urtikarija, izpuščaj Zelo redki – anafilaktične reakcije Med simptomi generalizirane preobčutljivosti so lahko generaliziran izpuščaj na koži, srbenje, znojenje, gastrointestinalne motnje, angionevrotični edem, težko dihanje, palpitacije, znižanje krvnega tlaka in omedlevica/ izguba zavesti.
19 4.9 Overdose
4. 9 Preveliko odmerjanje
A specific overdose of insulin cannot be defined.
Specifičnega prevelikega odmerjanja insulina ni mogoče definirati.
However, hypoglycaemia may develop over sequential stages: • Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products.
Zato je priporočljivo, da imajo diabetični bolniki pri sebi nekaj kock sladkorja, bonbone, piškote ali sadni sok, ki vsebuje sladkor.
It is therefore recommended that the diabetic patients carry some sugar lumps, sweets, biscuits or sugary fruit juice. • Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a person who has received appropriate instruction, or by glucose given intravenously by a medical professional.
19 • Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0, 5 do 1 mg), ki ga da intramuskularno ali subkutano ustrezno podučena oseba, ali z glukozo, ki jo da intravensko zdravstveni delavec.
20 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Izločanje Končni razpolovni čas je določen s hitrostjo absorpcije iz podkožnega tkiva.
6 weeks when used or carried as a spare (below 30°C).
6 tednov pri sobni temperaturi (do 30°C), če bolnik uporablja zdravilo ali ga ima pri sebi kot rezervo.
Do not store above 30°C.
Shranjujte pri temperaturi do 30 °C!
Keep the cartridge in the outer carton in order to protect from light.
Injekcijski vložek shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo!
3 ml glass cartridge (type 1) with a bromobutyl rubber plunger and a bromobutyl/ polyisoprene rubber stopper.
3 ml steklen vložek (steklo tipa 1) z batom iz brombutilne gume in brombutil/ poliizoprenskim gumijastim zamaškom.
The cartridge contains a glass ball to facilitate the re-suspension.
V vložku je steklena kroglica, ki olajša resuspendiranje.
1, 5 and 10 cartridges x 3 ml.
1, 5 in 10 vložkov po 3 ml.
21 6.6 Special precaustions for disposal and other handling
6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Cartridges should only be used in combination with products that are compatible with them and allow the cartridge to function safely and effectively.
Vložke se sme uporabljati samo s sistemi, s katerimi so kompatibilni in ki omogočajo varno in učinkovito delovanje vložkov.
Actraphane Penfill is for single person use only.
Actraphane Penfill je namenjen uporabi ene same osebe.
The container must not be refilled.
Vsebnika se ne sme znova polniti.
After removing Actraphane Penfill from the refrigerator it is recommended to allow the Penfill to reach room temperature (not above 25°C) before resuspending the insulin as instructed for first time use.
Potem ko Actraphane Penfill vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilu za prvo uporabo.
Any unused product or waste material should be disposed of in accordance with local requirements.
21 Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Actraphane 20 Penfill 100 IU/ ml suspension for injection in a cartridge.
Actraphane 20 Penfill 100 i. e. / ml suspenzija za injiciranje v injekcijskem vložku
Actraphane 20 consists of 20% dissolved insulin and 80% isophane insulin.
Actraphane 20 vsebuje 20% raztopljenega insulina in 80% insulina izofan.
23 Adjustment of dosage may also be necessary if patients change physical activity or their usual diet.
23 Prilagoditev odmerjanja utegne biti potrebna tudi v primeru, da bolniki spremenijo svojo telesno dejavnost ali običajno prehrano.
24 A few patients who have experienced hypoglycaemic reactions after transfer from animal source insulin have reported that early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin.
Maloštevilni bolniki, ki so po prehodu z insulina živalskega izvora doživeli hipoglikemije, so navedli, da so bili zgodnji opozorilni simptomi hipoglikemije manj izraziti ali so se razlikovali od tistih, ki so jih doživeli s prejšnjim insulinom.
25 hypoglycaemia or have frequent episodes of hypoglycaemia.
25 odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
26 4.9 Overdose
4. 9 Preveliko odmerjanje
It is therefore recommended that the diabetic patients carry some sugar lumps, sweets, biscuits or sugary fruit juice. • Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a person who has received appropriate instruction, or by glucose given intravenously by a medical professional.
26 • Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0, 5 do 1 mg), ki ga da intramuskularno ali subkutano ustrezno podučena oseba, ali z glukozo, ki jo da intravensko zdravstveni delavec.
27 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Izločanje Končni razpolovni čas je določen s hitrostjo absorpcije iz podkožnega tkiva.
28 6.6 Special precautions for disposal and other handling
6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Actraphane 30 Penfill 100 IU/ ml suspension for injection in a cartridge.
Actraphane 30 Penfill 100 i. e. / ml suspenzija za injiciranje v injekcijskem vložku
Cloudy, white, aqueous suspension.
otna, bela, vodna suspenzija.
30 Adjustment of dosage may also be necessary if patients change physical activity or their usual diet.
30 Prilagoditev odmerjanja utegne biti potrebna tudi v primeru, da bolniki spremenijo svojo telesno dejavnost ali običajno prehrano.
Actraphane is administered subcutaneously in the thigh or abdominal wall.
Actraphane se ponavadi injiciramo subkutano v stegno ali trebušno steno.
Continuous rotation of the injection site within a given area may help to
Stalno krožno menjavanje mest injiciranja na posameznem predelu pomaga zmanjšati ali preprečiti te reakcije.
31 reduce or prevent these reactions.
31 dneh do nekaj tednih.
32 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne previdnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia.
32 odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
33 4.9 Overdose
4. 9 Preveliko odmerjanje
However, hypoglycaemia may develop over sequential stages: • Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products.
Zato je priporočljivo, da imajo diabetični bolniki vedno pri sebi nekaj kock sladkorja, bonbone, piškote ali sadni sok, ki vsebuje sladkor.
It is therefore recommended that the diabetic patients carry some sugar lumps, sweets, biscuits or sugary fruit juice. • Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a person who has received appropriate instruction, or by glucose given intravenously by a medical professional.
33 • Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0, 5 do 1 mg), ki ga da intramuskularno ali subkutano ustrezno podučena oseba, ali z glukozo, ki jo da intravensko zdravstveni delavec.
34 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Izločanje Končni razpolovni čas je določen s hitrostjo absorpcije iz podkožnega tkiva.
Not all pack sizes may be marketed.
Na trgu ni vseh navedenihpakiranj.
35 6.6 Special precautions for disposal and other handling
6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Actraphane 40 Penfill 100 IU/ ml suspension for injection in a cartridge.
Actraphane 40 Penfill 100 i. e. / ml suspenzija za injiciranje v injekcijskem vložku
1 cartridge contains 3 ml equivalent to 300 IU.
Ena i. e.
Actraphane 40 consists of 40% dissolved insulin and 60% isophane insulin.
Actraphane 40 vsebuje 40% raztopljenega insulina in 60% insulina izofan.
37 Adjustment of dosage may also be necessary if patients change physical activity or their usual diet.
37 Prilagoditev odmerjanja utegne biti potrebna tudi v primeru, da bolniki spremenijo svojo telesno dejavnost ali običajno prehrano.
A few patients who have experienced hypoglycaemic reactions after transfer from animal source insulin have reported that early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin.
38 Maloštevilni bolniki, ki so po prehodu z insulina živalskega izvora doživeli hipoglikemije, so navedli, da so bili zgodnji opozorilni simptomi hipoglikemije manj izraziti ali so se razlikovali od tistih, ki so jih doživeli s prejšnjim insulinom.
39 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne previdnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
4.8 Undesirable effects
39 4. 8 Neželeni učinki
40 4.9 Overdose
40 intravensko zdravstveni delavec.
6 weeks when used or carried as a spare (below 30°C).
6 tednov pri temperaturi do 30°C, če bolnik uporablja zdravilo ali ga ima pri sebi kot rezervo.
42 Insulin preparations which have been frozen must not be used.
Pripravkov insulina, ki so bili zamrznjeni, se ne sme uporabiti.
Any unused product or waste material should be disposed of in accordance with local requirements.
42 Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Date of forst authorisation:
Datum pridobitve dovoljenja za promet:
Date of lates renewal:
Datum podaljšanja dovoljenja za promet:
Actraphane 50 Penfill 100 IU/ ml suspension for injection in a cartridge.
Actraphane 50 Penfill 100 i. e. / ml suspenzija za injiciranje v injekcijskem vložku
Actraphane 50 consists of 50% dissolved insulin and 50% isophane insulin.
Actraphane 50 vsebuje 50% raztopljenega insulina in 50% insulina izofan.
44 Adjustment of dosage may also be necessary if patients change physical activity or their usual diet.
44 Prilagoditev odmerjanja utegne biti potrebna tudi v primeru, da bolniki spremenijo svojo telesno dejavnost ali običajno prehrano.
45 A few patients who have experienced hypoglycaemic reactions after transfer from animal source insulin have reported that early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin.
Maloštevilni bolniki, ki so po prehodu z insulina živalskega izvora doživeli hipoglikemije, so navedli, da so bili zgodnji opozorilni simptomi hipoglikemije manj izraziti ali so se razlikovali od tistih, ki so jih doživeli s prejšnjim insulinom.
46 hypoglycaemia or have frequent episodes of hypoglycaemia.
46 odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
47 4.9 Overdose
4. 9 Preveliko odmerjanje
It is therefore recommended that the diabetic patients carry some sugar lumps, sweets, biscuits or sugary fruit juice. • Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a person who has received appropriate instruction, or by glucose given intravenously by a medical professional.
47 • Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0, 5 do 1 mg), ki ga da intramuskularno ali subkutano ustrezno podučena oseba, ali z glukozo, ki jo da intravensko zdravstveni delavec.
6 weeks when used or carried as a spare (below 30°C).
6 tednov pri temperaturi do 30 °C, če bolnik uporablja zdravilo ali ga ima pri sebi kot rezervo.
3 ml glass cartridge (type 1) with a bromobutyl rubber plunger and a bromobutyl/ polyisoprene rubber stopper.
3ml steklen vložek (steklo tipa 1) z batom iz brombutilne gume in brombutil/ poliizoprenskim gumijastim zamaškom.
49 Insulin preparations which have been frozen must not be used.
Pripravkov insulina, ki so bili zamrznjeni, se ne sme uporabiti.